The effect of naproxen-sodium on the intrauterine pressure and menstrual pain of dysmenorrheic patients.
The Prostaglandin-synthesis inhibitor: Naproxen-Sodium (NS) (an analgesic agent) very significantly (P less than 0.001) reduced the "resting" and "active" pressures and the frequency of cyclic uterine activity of 10 dysmenorrheic patients. It also highly significantly reduced (P less than 0.001) menstrual pain. Since these effects were observed after a single oral dose of 1100 mg NS, without side effects or complications, extensive field trials are recommended for assessing therapeutic benefits of this treatment.
D000328:Adult; D002986:Clinical Trials as Topic; D004412:Dysmenorrhea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009129:Muscle Tonus / Q000187:drug effects; D009280:Naphthaleneacetic Acids / Q000627:therapeutic use*; D009288:Naproxen / Q000494:pharmacology / Q000627:therapeutic use*; D010146:Pain; D010919:Placebos; D011293:Premenstrual Syndrome / Q000188:drug therapy; D014590:Uterine Contraction / Q000187:drug effects
D009280:Naphthaleneacetic Acids; D010919:Placebos; D009288:Naproxen